Taysha Gene Therapies, Inc. (TSHA) stock intrinsic value fair value estimate & owner earnings analysis

Taysha Gene Therapies is a clinical-stage biotechnology company whose near-term value hinges on one program: TSHA-102, a one-time gene therapy delivered directly into the spinal fluid for Rett syndrome, a severe neurodevelopmental disorder affecting girls. The company has no approved products and generates no meaningful revenue today. Early data are encouraging. Across the first 12 patients dosed in the initial Phase 1/2 study, patients gained or regained developmental milestones - communication, fine motor and gross motor skills - that would be extremely unlikely to occur without treatment, based on natural-history data for the disease, and there were no drug-related serious safety events. The company has aligned with the FDA on the design of its pivotal study (REVEAL, Part B), expects to finish dosing all pivotal-trial patients around mid-2026, and believes a planned six-month interim look at that data could support filing for approval - potentially about two quarters sooner than originally planned. A related safety-focused study (ASPIRE) is intended to support approval for a broader age range. The most important open question is not whether the drug looks promising - it does - but whether the FDA will accept a study built around comparison to historical, untreated patients rather than a traditional randomized control, given how few patients have been dosed so far. That is a real, disclosed regulatory design risk, not a hypothetical one. Financially, the company is well funded for its stage: roughly $455 million in cash as of mid-2026, against a modest $50 million term loan, funded largely through several rounds of new stock sales in recent years (shares outstanding have grown roughly eightfold since 2022). Spending on the pivotal trial and manufacturing scale-up has increased sharply as the company nears a potential filing, and management has said existing cash should last into 2028 - which lines up with when a first approval decision could realistically arrive. Because there is no approved product yet and the company has not disclosed how it would price or sell TSHA-102 if approved, this valuation does not attempt to guess at future product revenue - doing so would be speculation, not analysis. Instead, the estimate below is based mainly on the company's cash position, net of continuing near-term spending, through the point where the key clinical and regulatory questions are expected to be answered: - Less favorable case: the pivotal data or the FDA's view of it falls short, no approval is reached in the visible future, and the company must eventually scale back the program or fund it on tougher terms. Value reflects roughly what cash is likely to remain after about two more years of spending at the current pace, with no further credit given beyond that. - Middle case: the program proceeds on the timeline the company has described - dosing complete, interim data in hand, a filing in 2027, and an approval decision around 2028 - with spending moderating once pivotal-trial costs roll off, similar to how expenses fell sharply the last time the company narrowed its pipeline. - More favorable case: the interim data supports an earlier filing, spending comes down faster than in the middle case, and the company gains access to additional loan capacity that becomes available once a filing is submitted, reducing the need to sell more stock. None of these three cases puts a number on what an actual approval and launch would be worth - that could be substantially more than any figure here, but it isn't something we can size responsibly without company-provided pricing or sales expectations, which don't exist yet. That is the single biggest way this estimate could prove too conservative if the drug is approved and successfully launched. It is also the single biggest way it could prove too generous if the pivotal trial disappoints regulators. Given how much of the outcome depends on a small number of not-yet-reported results, the margin-of-safety price leaves a very large cushion for error - well below even the less-favorable case above. A materially higher margin-of-safety price could be justified once the six-month interim (or full pivotal) results come back clearly supportive of approval, since much of today's uncertainty would be resolved at that point.